FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Clarus Therapeutics Holdings, Inc. Stock AnalysisComprehensive stock analysis for Clarus Therapeutics Holdings, Inc. (CRXTQ) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCRXTQ
CRXTQ
Clarus Therapeutics Holdings, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
CRXTQ
Home🔹Stocks🔹Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc.

CRXTQ•OTC

Clarus Therapeutics Holdings, Inc.

CRXTQ•OTC
Market cap
$72.83K
Sentiment

Your view on CRXTQ

Mkt Cap
$72.83K
Sentiment
Your view
CRXTQ
Clarus Therapeutics Holdings, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
CRXTQ
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Clarus Therapeutics Holdings, Inc.

Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Robert E. Dudley
Headquarters
555 Skokie Boulevard, Northbrook, IL, US
Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Robert E. Dudley
Headquarters
555 Skokie Boulevard, Northbrook, IL, US
Description

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois. On September 5, 2022, Clarus Therapeutics Holdings, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News